BACKGROUND Elevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk of adverse outcomes in patients with CKD. Reducing dietary phosphate intake or absorption may decrease FGF23 levels, but data on the combined effects of dietary phosphate restriction and phosphate binders in CKD are limited. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS In this 2×2 factorial, ...

preventing increases in calcium-phosphate product, secondary hyperparathyroidism and ultimately VC. CKD patients develop extensive medial calcification, which contributes to higher cardiovascular morbidity and mortality [2] . In addition to elderly age, male gender, inflammation, mineral metabolism abnormalities and diabetes, new potential factors are emerging which help to better understand th...

BACKGROUND AND OBJECTIVES Ultrasonographic detection of subclinical atheromatosis is a noninvasive method predicting cardiovascular events. Risk factors predicting atheromatosis progression in CKD are unknown. Predictors of atheromatosis progression were evaluated in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Our multicenter, prospective, observational study included 155...

BACKGROUND Chronic kidney disease-mineral and bone disorder (CKD-MBD) has been linked to poor health outcomes, including diminished quality and length of life. This condition is characterized by high phosphate levels and requires phosphate-lowering agents-phosphate binders. The objective of this systematic review is to compare the effects of available phosphate binders on patient-important outc...

BACKGROUND Hyperphosphatemia is an important contributor to cardiovascular calcification in chronic renal failure (CRF) patients. Cardiovascular calcifications are responsible for the high morbidity and mortality in patients undergoing hemodialysis (HD). Despite dietary phosphate reduction and treatment with phosphate binders, serum phosphorus level, as recommended by K/DOQI guidelines, is achi...

Phosphate removal is both biologically and environmentally important. Biologically, hyperphosphatemia is a critical condition in end-stage chronic kidney disease patients. Patients with hyperphosphatemia are treated long-term with oral phosphate binders to prevent phosphate absorption to the body by capturing phosphate in the gastrointestinal (GI) tract followed by fecal excretion. Environmenta...

Hyperphosphatemia causes endothelial dysfunction as well as vascular calcification. Management of serum phosphate level by dietary phosphate restriction or phosphate binders is considered to be beneficial to prevent chronic kidney disease patients from cardiovascular disease, but it has been unclear whether keeping lower serum phosphate level can ameliorate endothelial dysfunction. In this stud...

the aim of this research is to assess the impact of clinical pharmacist-provided education on medication adherence in haemodialysis patients. ninety haemodialysis patients were randomized into two groups. brief medication questionnaire (bmq), a tool for screening adherence was administered to both groups at the baseline to assess adherence to antihypertensives, vitamin d analogues, phosphate bi...

modialysis patients, behavioral changes associated with the management of hyperphosphatemia, such as the adoption of a low phosphate diet and judicious intake of phosphate binders, are probably the most complicated and challenging [1,2]. Non-adherence to low phosphate diets, which are likely the most common dietary restrictions required from this patient population, ranges between 19 and 57% [3...

BACKGROUND AND OBJECTIVES Fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality in patients with ESRD. Before FGF23 testing can be integrated into clinical practice of ESRD, further understanding of its determinants is needed. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS In a study of 67 adults undergoing peritoneal dialysis, we tested the hypothesis that longer dia...